Results 11 to 20 of about 37,525 (284)

Efficacy of Praziquantel for the Treatment of Human Schistosomiasis in Ethiopia: A Systematic Review and Meta-Analysis

Journal of Tropical Medicine, 2021
Background. Schistosomiasis is one of the neglected tropical diseases causing a serious human health problem in Ethiopia. Praziquantel is the only drug that has been used for the treatment of human schistosomiasis in the country.
Tamirat Hailegebriel, Endalkachew Nibret, Abaineh Munshea   +2 more
doaj   +2 more sources

Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni

Parasites & Vectors, 2020
Background The control of schistosomiasis has been centered to date on a single drug, praziquantel, with shortcomings including treatment failure, reinfection, and emergence of drug resistance. Drug repurposing, combination therapy or nanotechnology were
Maha M. Eissa, Mervat Z. El-Azzouni, Labiba K. El-Khordagui, Amany Abdel Bary, Riham M. El-Moslemany, Sara A. Abdel Salam   +5 more
doaj   +2 more sources

Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial.

PLoS Neglected Tropical Diseases, 2020
BackgroundDespite the reported success in reducing morbidity, praziquantel alone is insufficient for the control and elimination of schistosomiasis, partly due to its poor efficacy against the juvenile worms. Artemisinin derivatives are effective against
Rajabu Hussein Mnkugwe, Omary Minzi, Safari Kinung'hi, Appolinary Kamuhabwa, Eleni Aklillu   +4 more
doaj   +2 more sources

Praziquantel, Mefloquine-Praziquantel, and Mefloquine-Artesunate-Praziquantel against Schistosoma haematobium: A Randomized, Exploratory, Open-Label Trial [PDF]

PLoS Neglected Tropical Diseases, 2014
Treatment and morbidity control of schistosomiasis relies on a single drug, praziquantel. Hence, there is a pressing need to develop additional therapeutics against schistosomiasis. The antimalarial drug mefloquine shows antischistosomal activity in animal models and clinical trials, which calls for further investigations.We comparatively assessed the ...
Jennifer Keiser, Kigbafori D. Silué, Lukas K. Adiossan, Nicaise A. N'Guessan, N'Chou Monsan, Jüerg Utzinger, Eliézer K. N'Goran   +6 more
openaire   +7 more sources

Evidence Against Rapid Emergence of Praziquantel Resistance in Schistosoma haematobium, Kenya [PDF]

Emerging Infectious Diseases, 2000
We examined the long-term efficacy of praziquantel against Schistosoma haematobium, the causative agent of urinary schistosomiasis, during a school-based treatment program in the Msambweni area of Coast Province, Kenya, where the disease is highly ...
Charles H. King, Eric M. Muchiri, John H. Ouma   +2 more
doaj   +2 more sources

Seizures and Praziquantel. A case report [PDF]

Revista do Instituto de Medicina Tropical de São Paulo, 1988
A 27 year Old male developed seizures after receiving a single 20 mg/kg dose of praziquantel for the treatment of an intestinal Hymenolepis nana infection. On further clinical and laboratorial evaluations, he was found to suffer from an until then asymptomatic parenchymal brain cysticercosis.
Torres R., Jaime R., Noya G., Oscar, Noya, Belkysyolé A. de, Mondolfi G., Alejandro   +3 more
openaire   +7 more sources

Reduced efficacy of praziquantel against Schistosoma mansoniis associated with multiple rounds of mass drug administration [PDF]

Clinical Infectious Diseases, 2016
Background: Mass drug administration (MDA) with praziquantel is the cornerstone of schistosomiasis control in sub-Saharan Africa. The effectiveness of this strategy is dependent on the continued high efficacy of praziquantel; however, drug efficacy is ...
Cotton, James A., Crellen, Thomas, Kabatereine, Narcis B., Lamberton, Poppy H.L., Tukahebwa, Edridah M., Walker, Martin, Webster, Joanne P.   +6 more
core   +5 more sources

Low Praziquantel Treatment Coverage for Schistosoma mansoni in Mayuge District, Uganda, Due to the Absence of Treatment Opportunities, Rather Than Systematic Non-Compliance

Tropical Medicine and Infectious Disease, 2018
The World Health Organization (WHO) recommends praziquantel mass drug administration (MDA) to control schistosomiasis in endemic regions. We aimed to quantify recent and lifetime praziquantel coverage, and reasons for non-treatment, at an individual ...
Moses Adriko, Christina L. Faust, Lauren V. Carruthers, Arinaitwe Moses, Edridah M. Tukahebwa, Poppy H. L. Lamberton   +5 more
doaj   +2 more sources

Two-year longitudinal survey reveals high genetic diversity of Schistosoma mansoni with adult worms surviving praziquantel treatment at the start of mass drug administration in Uganda

Parasites & Vectors, 2019
Background A key component of schistosomiasis control is mass drug administration with praziquantel. While control interventions have been successful in several endemic regions, mass drug administration has been less effective in others. Here we focus on
Christina L. Faust, Marco Crotti, Arinaitwe Moses, David Oguttu, Aidah Wamboko, Moses Adriko, Elizabeth K. Adekanle, Narcis Kabatereine, Edridah M. Tukahebwa, Alice J. Norton, Charlotte M. Gower, Joanne P. Webster, Poppy H. L. Lamberton   +12 more
doaj   +2 more sources

Ground Calcium Carbonate as a Low Cost and Biosafety Excipient for Solubility and Dissolution Improvement of Praziquantel

Pharmaceutics, 2019
Calcium carbonate is an abundant mineral with several advantages to be a successful carrier to improve oral bioavailability of poorly water-soluble drugs, such as praziquantel.
Ana Borrego-Sánchez, Rita Sánchez-Espejo, Beatrice Albertini, Nadia Passerini, Pilar Cerezo, César Viseras, C. Ignacio Sainz-Díaz   +6 more
doaj   +2 more sources